CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 84 enrolled
Drug / intervention
INCB000928 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04455841
NCT04455841Phase 2Active
CompareCT.gov

A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Incyte Corporation·interventional·Posted Jul 2, 2020·Updated May 14, 2026

In Brief

A Phase 2 clinical trial evaluating INCB000928 and ruxolitinib for Anemia and 2 related conditions. Active but no longer recruiting, targeting 84 participants across 34 sites in 6 countries.

Detailed Summary

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
CountriesCanada, France, Italy, Japan, United Kingdom, United States
Collaborators--

Timeline

Phase 2Active
20212022202320242025202620272028
First PostedJul 2, 2020
Enrollment StartMar 19, 2021
Primary CompletionApr 1, 2025
Study CompletionNov 26, 2027
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 6 years ago

Interventions

INCB000928drug

INCB000928 will be administered at protocol defined dose.

ruxolitinibdrug

Ruxolitinib will be administered at protocol defined dose.